vocimagene amiretrorepvec

AXP000126.1 · Oncolytic virus

Platform
replicating gammaretroviral vector (amphotropic MLV-based)
Originator
Tocagen
Sponsor
Tocagen

Names

NameTypeSource
vocimagene amiretrorepvecpreferred name, INNcurator, ncit
Toca 511codencit

Virus

Role
Oncolytic
Family
Retroviridae
Virus
murine leukemia virus (NCBI Taxonomy 11786)
Strain
amphotropic MLV-based replicating vector
Replication
replicating
Modifications
replication-competent retroviral vector carrying an optimised yeast cytosine deaminase cassette
Transgenes
yeast cytosine deaminase (CD)
Route
intracerebral, intravenous
Source
evidence

Cross-references

NCI Thesaurus
C91734
FDA UNII
DC4WO3WA4Q

Approvals

No regulatory approval recorded.

Clinical trials (10)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06504381DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade GliomaRecruitingPhase 1/22025-01-082028-01-3170High Grade Glioma; MGMT-Methylated Glioblastoma; MGMT-Unmethylated Glioblastoma
NCT04105374Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed GlioblastomaWithdrawnPhase 2/32020-01-312025-11-300Anaplastic Astrocytoma; Glioblastoma; Oligodendroglioma; Supratentorial Glioblastoma
NCT04089163A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)WithdrawnPhase 12019-122022-010Bladder Cancer
NCT02598011A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of CareWithdrawnPhase 12017-012022-110Newly Diagnosed High Grade Glioma (HGG)
NCT02576665A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)TerminatedPhase 12016-072019-0521Bladder Cancer; Colorectal Cancer; Head and Neck Cancer; IDH1 Mutated Solid Tumors; IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting); Lymphoma; Melanoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Sarcoma; Triple Negative Breast Cancer
NCT02414165The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade GliomaTerminatedPhase 2/32015-11-302019-05-31403Anaplastic Astrocytoma; Glioblastoma Multiforme
NCT01985256Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain TumorCompletedPhase 12014-022016-03-0317Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Anaplastic Oligodendroglioma; Glioblastoma Multiforme
NCT01470794Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain TumorCompletedPhase 12012-022016-04-1258Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Anaplastic Oligodendroglioma; Glioblastoma Multiforme
NCT04327011A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511TerminatedPhase 12011-022019-1265Astrocytoma; Glioblastoma Multiforme; Gliomas, Malignant
NCT01156584A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant GliomaCompletedPhase 12010-072016-08-1854Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Anaplastic Oligodendroglioma; Glioblastoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40842153A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects.Molecular therapy : the journal of the American Society of Gene Therapy2025name in title: vocimagene amiretrorepvec
PMID 32816892Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma.Clinical cancer research : an official journal of the American Association for Cancer Research2020name in title: vocimagene amiretrorepvec
PMID 33119048Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.JAMA oncology2020cited by trial NCT02414165
PMID 29322091A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models.Molecular therapy oncolytics2018cited by trial NCT02576665
PMID 29735994Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer.Cancer gene therapy2018cited by trial NCT02576665
PMID 29762717Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.Neuro-oncology2018cited by trial NCT01470794
PMID 29945998Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients.Clinical cancer research : an official journal of the American Association for Cancer Research2018name in title: Toca 511
PMID 27252174Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.Science translational medicine2016cited by trial NCT02414165

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 39039195Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model.Cancer gene therapy2024name in abstract: Toca 511
PMID 34004331Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme.Seminars in cancer biology2022name in abstract: Toca 511
PMID 36497300Retroviral Replicating Vector Toca 511 (Vocimagene Amiretrorepvec) for Prodrug Activator Gene Therapy of Lung Cancer.Cancers2022name in title: vocimagene amiretrorepvec
PMID 33724117Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer.Expert opinion on biological therapy2021name in title: Toca 511
PMID 34321837Current evidence and challenges of systematic therapies for adult recurrent glioblastoma: Results from clinical trials.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu2021name in abstract: vocimagene amiretrorepvec
PMID 30676111Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.Expert opinion on investigational drugs2019name in title: Toca 511
PMID 29117980Treating Recurrent Glioma with Toca 511.Cancer discovery2018name in title: Toca 511
PMID 29216761Efficient Therapeutic Protein Expression Using Retroviral Replicating Vector with 2A Peptide in Cancer Models.Human gene therapy2018name in abstract: Toca 511
PMID 30563098Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?Cancers2018name in abstract: Toca 511
PMID 28387831Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.Neuro-oncology2017name in abstract: Toca 511
PMID 28387849Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.Neuro-oncology2017name in title: Toca 511
PMID 26467507Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.Human gene therapy methods2016name in abstract: Toca 511
PMID 27166379Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.Neuro-oncology2016name in title: Toca 511
PMID 27861411"Tag Team" Glioblastoma Therapy: Results From a Phase 1 Trial of Toca 511 and 5-Fluorocytosine for Recurrent High-Grade Glioma.Neurosurgery2016name in title: Toca 511
PMID 25419577Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.Human gene therapy2015name in title: Toca 511
PMID 24941977Immunotherapy for high-grade glioma.Future oncology (London, England)2014name in abstract: Toca 511
PMID 24965455Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity.Journal of virology2014name in abstract: Toca 511
PMID 25301172Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.Cancer gene therapy2014name in abstract: Toca 511
PMID 26015967Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids.Molecular therapy. Methods & clinical development2014name in abstract: Toca 511
PMID 23969884Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.Cancer gene therapy2013name in title: Toca 511
PMID 28160846Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression.Molecular therapy : the journal of the American Society of Gene Therapy2013name in title: Toca 511
PMID 22070930Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.Neuro-oncology2012name in abstract: Toca 511
PMID 22547150Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.Molecular therapy : the journal of the American Society of Gene Therapy2012name in title: Toca 511

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R21CA282543A Phase 2 biomarker driven, Study of DB107, a Retroviral Replicating Vector, Combined With 5-FC in Patients with Recurrent Glioblastoma or Anaplastic AstrocytomaUNIVERSITY OF MIAMI SCHOOL OF MEDICINESHAH, ASHISH HARISH2023–2024name in abstract: vocimagene amiretrorepvec
R01CA213119Retroviral Replicating Vector-mediated Gene Therapy for Ovarian CancerUNIVERSITY OF CALIFORNIA, SAN FRANCISCOKASAHARA, NORIYUKI2017–2022name in abstract: Toca 511
R33NS104454GALV-Based Retroviral Replicating Vectors for Glioma Gene TherapyUNIVERSITY OF CALIFORNIA, SAN FRANCISCOKASAHARA, NORIYUKI2021–2021name in abstract: Toca 511
R21NS104454GALV-Based Retroviral Replicating Vectors for Glioma Gene TherapyUNIVERSITY OF CALIFORNIA, SAN FRANCISCOKASAHARA, NORIYUKI2019–2020name in abstract: Toca 511
R01FD005732Phase 2/3 Study of Toca 511-Toca FC vs SOC in Recurrent GBM-AA IND 14173 9Jul2015TOCAGEN, INC.VISONNEAU, SOPHIE2017–2019name in title: Toca 511
R43CA174090Retroviral replicating vector for prodrug activator gene therapyTOCAGEN, INC.JOLLY, DOUGLAS J.2012–2012name in abstract: vocimagene amiretrorepvec

Notes

Replication-competent retroviral vector (Toca 511) delivering optimised yeast cytosine deaminase, which converts the companion prodrug 5-fluorocytosine (Toca FC, extended-release flucytosine) to 5-FU. Toca FC is a small molecule and not a separate virus program. Phase 3 Toca 5 missed its overall survival endpoint in September 2019; Tocagen merged into Forte Biosciences in 2020 and the programme ended.

How to cite

vocimagene amiretrorepvec (AXP000126.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000126.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.